September 15, 2017 (Vol. 37, No. 16)

John Sterling Editor in Chief Genetic Engineering & Biotechnology News

GEN Put Together This Special Supplement on Continuous Bioprocessing to Give Our Readers Up-to-Date Information

The next major step for the biopharmaceutical industry could be the adoption of integrated continuous bioprocessing on a broad scale for biologics manufacturing. The biopharma industry’s interest in continuous processing is driven by expectations of reducing cost, improving quality, and increasing productivity.

The key to its success, however, is the availability of novel upstream and downstream technologies that will not only reduce facility footprint and capital expenses but will also increase process flexibility and further facilitate the utilization of single-use and/or disposable technologies.

GEN put together this special supplement on continuous bioprocessing to give our readers up-to-date information about the current state of the approach and to suggest when and where it will be more widely adopted. The articles include:

Continuous Bioprocessing Is Coming
Integrated Continuous Manufacturing of Biologics
Continuous Bioprocessing: Is It for Everyone?
Moving toward Continuous Bioprocessing
Bioburden Control in Continuous Capture of Monoclonal Antibodies
Single-Use Sensors in Continuous Bioprocessing
MilliporeSigma Sees Opportunity in Continuous Processing
Case Study: Insulin Increases Influenza Virus Yield

As you learn more about continuous bioprocessing, from this GEN supplement and other sources, you might decide it’s worth exploring for your own company’s biomanufacturing operations. We wish you the best of success in all your bioprocessing activities.


John Sterling, Editor in Chief of GEN






























This site uses Akismet to reduce spam. Learn how your comment data is processed.